Furosemide (Ascites / Cirrhosis)
Brand names: Lasix, Frusemide
This is the use of furosemide, a loop diuretic, in managing fluid overload and ascites associated with cirrhosis, typically alongside the aldosterone antagonist spironolactone.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Furosemide inhibits the sodium-potassium-chloride co-transporter in the thick ascending limb of the loop of Henle, producing a potent diuresis that helps mobilise ascitic and oedema fluid.
Prescribing in practice
- In cirrhotic ascites furosemide is usually combined with spironolactone rather than used alone, and overly rapid diuresis must be avoided as it can precipitate hypovolaemia, renal impairment and hepatic encephalopathy.
- It can cause hypokalaemia, hyponatraemia and metabolic alkalosis, which are particularly hazardous in liver disease and warrant close electrolyte surveillance.
- Diuretics should be withheld if there is hyponatraemia, worsening renal function, tense or refractory ascites needing paracentesis, or clinical encephalopathy.
Monitoring
Monitor body weight, renal function and electrolytes regularly, titrating the diuretic to a controlled rate of weight loss rather than aggressive fluid removal.
Counselling the patient
- You will be weighed regularly so the dose can be adjusted to remove fluid gradually and safely.
- Report increasing confusion, drowsiness, severe thirst or cramps, as these may mean the dose needs changing.
Evidence & guidelines
Combined spironolactone and furosemide diuretic therapy is the established standard for managing cirrhotic ascites in national and international guidance.
Reference: EASL Cirrhosis Guidelines 2018; Baveno VII Consensus 2022; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021